Durability of Sustained Virologic Response in Chronic Hepatitis C: Analysis of Factors Related to Relapse after Sustained Virologic Response with Peginterferon Plus Ribavirin Combination Therapy.
10.4166/kjg.2011.57.3.173
- Author:
Jang Eun LEE
1
;
Na Ri YOON
;
Jin Dong KIM
;
Myeong Jun SONG
;
Jung Hyun KWON
;
Si Hyun BAE
;
Jong Young CHOI
;
Sung Won JEONG
;
Seung Kew YOON
Author Information
1. Department of Internal Medicine, WHO Collaborating Center on Viral Hepatitis, The Catholic University of Korea College of Medicine, Seoul, Korea. yoonsk@catholic.ac.kr
- Publication Type:Original Article ; English Abstract
- Keywords:
Hepatitis C;
Peginterferon;
Sustained virologic response;
Durability
- MeSH:
Adult;
Aged;
Antiviral Agents/*therapeutic use;
Drug Therapy, Combination;
Female;
Genotype;
Hepatitis C, Chronic/complications/*drug therapy;
Humans;
Interferon Alfa-2a/*therapeutic use;
Interferon Alfa-2b/*therapeutic use;
Liver Cirrhosis/complications;
Logistic Models;
Male;
Middle Aged;
Polyethylene Glycols/*therapeutic use;
RNA, Viral/blood;
Recurrence;
Ribavirin/*therapeutic use;
Risk Factors
- From:The Korean Journal of Gastroenterology
2011;57(3):173-179
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Pegylated interferon plus ribavirin combination therapy has been the standard of therapy for patients with chronic hepatitis C. Although previous studies have reported long term durability after the sustained virologic response (SVR) with standard therapy for chronic hepatitis C, it is still unclear in Korea. The aim of this study was to evaluate the relapse rate and related factors after SVR to pegylated interferon therapy in Korean patients with chronic hepatitis C. METHODS: A total of 119 chronic hepatitis C patients were treated with pegylated interferon plus ribavirin, and 73 patients achieved SVR (61.3%). Among 73 patients who achieved SVR, 68 patients (genotype 1, n=40; genotype non-1, n=28) were evaluated for virological response after SVR. RESULTS: SVR rate in genotype 1 and genotype non-1 were 52.5%, and 65.1%, respectively. Relapse after SVR occurred in 5 patients (7.4%) with genotype 1, and the median time to relapse from SVR was 10 months. Univariate analysis revealed that the dose reduction of pegylated interferon (p=0.005) and cirrhosis (p=0.03) were significantly associated with relapse. CONCLUSIONS: These results suggested that the relapse could occur even after SVR achievement in Korean patients with chronic hepatitis C, and the dose reduction of pegylated interferon during treatment or having cirrhosis may increased the risk for relapse.
